<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497873</url>
  </required_header>
  <id_info>
    <org_study_id>11SCLC09I</org_study_id>
    <nct_id>NCT01497873</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer</brief_title>
  <official_title>A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Belotecan administered 5
      days every 3 weeks in comparison to Topotecan in Patients with relapsed small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and
      Safety of Belotecan(CamtoBell inj.) or Topotecan in Patients with Relapsed Small Cell Lung
      Cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objectives Response Rate(ORR, %)</measure>
    <time_frame>Up to 18weeks</time_frame>
    <description>The response rate was defined as the test subject who had a complete response (CR) or a partial response (PR) as determined by the 'tumor response evaluation' criteria specified in the research protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>7years</time_frame>
    <description>Defined as the time from the randomization to the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival(PFS)</measure>
    <time_frame>Up to 18weeks</time_frame>
    <description>Defined as the elapsed time from the time of randomization to the time of confirmation of progression or the time of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Belotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camtobell Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hycamtin Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more</description>
    <arm_group_label>Topotecan</arm_group_label>
    <other_name>Hycamtin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belotecan</intervention_name>
    <description>0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more</description>
    <arm_group_label>Belotecan</arm_group_label>
    <other_name>Camtobell Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Histological or cytological diagnosis of SCLC

          -  Limited disease (LD) or Extensive disease (ED) at time of study entry

          -  Recurrent or progressive SCLC ≥ 90 days of duration of response for firstline therapy

          -  Measurable disease defined by RECIST criteria

          -  ECOG Performance Status of 0, 1, or 2

          -  Life expectancy ≥ 3 months

          -  Adequate bone marrow, Renal, Hepatic reserve:

        absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/mm3 platelet count ≥
        100,000 cells/ mm3 hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 mm3 Alanine aminotransferase
        (ALT) and aspartate aminotransferase(AST) ≤ 2.0 X ULN Alkaline Phosphatase (ALP) ≤ 2.0 X
        ULN Serum creatinine ≤ 1.5mg/dL or calculated creatinine clearance &gt; 60mL/min

        - Signed a written informed consent

        Exclusion Criteria:

          -  Active infection

          -  Symptomatic brain lesion

          -  Any other type of cancer during the previous 5 years

          -  Severe concurrent diseases

          -  Prior anticancer therapy within 4 weeks before enroll

          -  Active pregnancy test and Pregnant or nursing women

          -  Participation in any investigational drug study within 28 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heung Tae Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Hyoung Kang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea Seoul St. Marys Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Young Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Wan Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-We Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hye Ryeon Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Hyuk Choi, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Hyeong Lee, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Jung An, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincents Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi Hoon Maeng, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Medical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Soo Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joung Soon Jang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Choung Ang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bong Seog Kim, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Veterans Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo-Hang Kim, .D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Bundang Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Marys Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>December 25, 2018</last_update_submitted>
  <last_update_submitted_qc>December 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Belotecan</keyword>
  <keyword>Topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Belotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

